Fenpentadiol Routes of administration Oral ATC code Legal status
In general: ℞ (Prescription only)
2-(4-chlorophenyl)-4-methyl-pentane-2,4-diol
CAS Number PubChem CID ChemSpider UNII ChEMBL CompTox Dashboard (EPA ) ECHA InfoCard 100.036.150 Formula C 12 H 17 Cl O 2 Molar mass 228.72 g·mol−1
Fenpentadiol (INN ) (brand names Tredum , Trefenum ; developmental code name Rd-292 ), also known as phenpentanediol , is a drug described as a tranquilizer and antidepressant that was formerly marketed in Europe .[1] [2] It also has stimulant , sedative , and anxiolytic effects, with the latter two occurring only at higher doses.[3] [4]
The following literature incidence of the fenpentadiol has been found and quoted:
In three articles the properties of a new psychotropic agent from the series of araliphatic alcohols — phenpentanediol (CXV) — were described (477-479). It is not easy to place this substance anywhere in the pharmacodynamic system of psychotropic agents: on the one hand it potentiates the barbiturate narcosis, on the other it increases motility and exploratory activity in mice and potentiates the effects of amphetamine.
References [ ]
Stimulants
Adamantanes
Adapromine
Amantadine
Bromantane
Memantine
Rimantadine
Adenosine antagonists Alkylamines Ampakines Arylcyclohexylamines Benzazepines
6-Br-APB
SKF-77434
SKF-81297
SKF-82958
Cathinones Cholinergics Convulsants Eugeroics Oxazolines Phenethylamines Phenylmorpholines Piperazines
2C-B-BZP
3C-PEP
BZP
CM156
DBL-583
GBR-12783
GBR-12935
GBR-13069
GBR-13098
GBR-13119
MeOPP
MBZP
oMPP
Vanoxerine
Piperidines Pyrrolidines Racetams
Oxiracetam
Phenylpiracetam
Phenylpiracetam hydrazide
Tropanes Tryptamines Others ATC code : N06B
Antidepressants (N06A )
SSRIs
Citalopram
Escitalopram
Fluoxetine #
Fluvoxamine
Indalpine ‡
Paroxetine
Sertraline
Zimelidine ‡
SNRIs
Desvenlafaxine
Duloxetine
Levomilnacipran
Milnacipran
Tofenacin
Venlafaxine
NRIs
Atomoxetine
Reboxetine
Viloxazine
NDRIs
Amineptine ‡
Bupropion
Nomifensine ‡
NaSSAs SARIs
Etoperidone
Nefazodone
Trazodone
SMS Others
Tricyclic and tetracyclic antidepressants
TCAs
Amineptine ‡
Amitriptyline #
Amitriptylinoxide
Butriptyline ‡
Clomipramine #
Demexiptiline ‡
Desipramine
Dibenzepin
Dimetacrine ‡
Dosulepin
Doxepin
Imipramine
Imipraminoxide ‡
Iprindole ‡
Lofepramine
Melitracen
Metapramine ‡
Nitroxazepine
Nortriptyline
Noxiptiline
Opipramol
Pipofezine
Propizepine ‡
Protriptyline
Quinupramine ‡
Tianeptine
Trimipramine
TeCAs
Amoxapine
Maprotiline
Mianserin
Mirtazapine
Setiptiline
Others
Monoamine oxidase inhibitors
Non-selective MAOA -selectiveMAOB -selective
Adjunctive therapies
Atypical antipsychotics (aripiprazole , brexpiprazole , lurasidone , olanzapine , quetiapine , risperidone )
Buspirone
Lithium (lithium carbonate , lithium citrate )
Thyroid hormones (triiodothyronine (T3 ), levothyroxine (T4 ))
Miscellaneous
Ademetionine (SAMe )
Hypericum perforatum (St. John's Wort)
Oxitriptan (5-HTP )
Rubidium chloride (RbCl)
Tryptophan
# WHO-EM
‡ Withdrawn from market
Clinical trials :
† Phase III
§ Never to phase III
Anxiolytics (N05B )
5-HT1A R agonists GABAA R PAMs
Benzodiazepines : Adinazolam
Alprazolam
Bromazepam
Camazepam
Chlordiazepoxide
Clobazam
Clonazepam
Clorazepate
Clotiazepam
Cloxazolam
Diazepam #
Ethyl loflazepate
Etizolam
Fludiazepam
Halazepam
Ketazolam
Lorazepam #
Medazepam
Nordazepam
Oxazepam
Pinazepam
Prazepam ; Others: Alpidem ‡
Barbiturates (e.g., phenobarbital )
Carisoprodol
Carbamates (e.g., meprobamate )
Chlormezanone ‡
Ethanol (alcohol)
Etifoxine
Imepitoin ; Herbs:
Kava
Skullcap
Valerian
Gabapentinoids (α2 δ VDCC blockers )
Gabapentin
Gabapentin enacarbil
Phenibut
Pregabalin
Antidepressants
SSRIs (e.g., escitalopram )
SNRIs (e.g., duloxetine )
SARIs (e.g., trazodone )
TCAs (e.g., clomipramine # )
TeCAs (e.g., mirtazapine )
MAOIs (e.g., phenelzine ); Others: Agomelatine
Bupropion
Tianeptine
Vilazodone
Vortioxetine
Sympatholytics (Antiadrenergics )
Alpha-1 blockers (e.g., prazosin )
Alpha-2 agonists (e.g., clonidine , dexmedetomidine , guanfacine )
Beta blockers (e.g., propranolol )
Others
Benzoctamine
Cannabidiol
Cycloserine
Fabomotizole
Hydroxyzine
Kanna
Lavender
Lorpiprazole
Mebicar
Mepiprazole
Nicotine
Opipramol
Oxaflozane ‡
Phenaglycodol
Phenibut
Picamilon
Selank
Tiagabine
Tofisopam
Validolum
# WHO-EM
‡ Withdrawn from market
Clinical trials :
† Phase III
§ Never to phase III